Wall Street closes at a record for the first time since end of January
President Trump signed an executive order Thursday imposing 100% tariffs on imported patented pharmaceuticals, and 13 drug companies are already exempt. That gap between the tariff wall and the companies standing safely behind it is where the trade lives.
The order, issued under Section 232 of the Trade Expansion Act, creates a tiered system that punishes drugmakers who haven’t cut deals with the White House while rewarding those who have. Companies that signed Most Favored Nation pricing agreements and committed to building U.S. manufacturing facilities face a 0% tariff through January 2029. Everyone else? They’re staring down a 100% levy in 120 days.
This isn’t a negotiating tactic anymore. It’s law. And the clock is ticking.
The Deal Structure Matters More Than the Headline
Here’s what most coverage gets wrong: the 100% rate grabs attention, but the exemption architecture is the real story. Trump’s team has already secured 17 pricing deals with major drugmakers, 13 of which are fully signed. Those companies — including Eli Lilly (NYSE:LLY), Pfizer (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Novartis (NYSE:NVS), Sanofi (NASDAQ:SNY), and GSK — pay zero tariffs on their branded drugs through 2029.
Companies that haven’t signed but commit to onshoring get a 20% rate. Those that do nothing? The full 100% hits on July 31 for large companies and September 29 for smaller firms. Generics and biosimilars are exempt entirely.
The country-level tiers add another layer. Drugs imported from the EU, Japan, Korea, and Switzerland face a 15% tariff regardless of deal status. The UK gets 10%. Products from China, India, and Singapore that are major manufacturing hubs with no trade framework in place, face the full 100%.
"These developments offer Street additional confidence that policy overhangs are indeed abating," Citi analysts wrote when the earlier MFN deals were announced in December, adding that the deals "help strengthen the sector’s recent momentum into 2026." The latest executive order crystallizes that thesis into hard policy.
$150 Billion Onshoring Wave Is Real
The tariff threat has already triggered the largest pharmaceutical manufacturing buildout in American history. Collectively, the companies that signed MFN deals have pledged over $150 billion in domestic manufacturing investments. GSK committed $30 billion. Sanofi pledged $20 billion. J&J invested $2 billion into a Fujifilm Biotechnologies CDMO facility in North Carolina for large-scale cell culture manufacturing.
This isn’t hypothetical. Repligen CEO Olivier Loeillot told investors at a November conference that even "a fraction of the total announcements, or $50 to $100 billion, would still offer high-growth potential for the equipment industry," with construction timelines beginning in 2026 and 2027.
The ripple effects extend beyond the pharma companies themselves. U.S.-based contract development and manufacturing organizations are expected to see a surge in demand as smaller drugmakers without their own domestic facilities scramble to comply before the tariff deadlines. Real estate developers specializing in life sciences facilities and construction firms with sterile manufacturing expertise stand to benefit from a multi-year buildout cycle.
How to Play It
Eli Lilly (LLY) — The crown jewel. At around $936, Lilly is the single best-positioned pharma company in America right now. It signed an MFN deal, has the most valuable pipeline in the industry anchored by GLP-1 blockbusters Mounjaro and Zepbound, and the FDA just approved its oral obesity pill on April 1. CEO David Ricks has emphasized domestic manufacturing capacity throughout the company’s expansion. Wall Street’s consensus target sits at $1,201 — 28% upside — and 20 out of 20 analysts rate it Strong Buy. Earnings due April 30, where the company is expected to post $7.54 EPS, a 126% year-over-year jump.
Johnson & Johnson (JNJ) — The defensive anchor. At around $244, J&J trades just below its all-time high of $248.56. The company signed its MFN deal in January and backed it with a $2 billion onshoring investment through Fujifilm Biotechnologies’ new North Carolina facility. JNJ’s diversified portfolio across pharmaceuticals and medtech means tariff exposure was already lower than pure-play pharma peers. The stock yields 2.4% and has increased its dividend for 62 consecutive years. An FDA psoriasis pill approval in March added another growth driver. Earnings report due April 15.
Pfizer (PFE) — The turnaround play. At around $28.69, Pfizer sits at its 52-week high after signing one of the first MFN deals back in October 2025. That early-mover advantage is paying off — the stock has rallied 37% from its 52-week low of $20.92 as the tariff exemption and a stabilizing revenue base have rebuilt investor confidence. Pfizer projects 2026 revenue between $59.5 billion and $62.5 billion with blockbuster drugs Vyndaqel and Padcev driving growth beyond COVID products. The 6% dividend yield provides a floor. Earnings due May 5.
Amgen (AMGN) — The biotech wildcard. At around $351, Amgen combines MFN deal protection with the most exciting obesity pipeline outside Lilly. Its MariTide candidate is the only late-stage obesity drug offering monthly to quarterly dosing flexibility, a potential game-changer in a market dominated by weekly injections. CEO Bob Bradway has positioned 2026 as "a springboard year," with 2025 revenue of $36.75 billion up 10% year-over-year. Biosimilar sales have generated $13 billion since 2018, proving Amgen can manufacture at scale domestically. Earnings due April 29.
Health Care Select Sector SPDR ETF (NYSE:XLV) — For investors who want broad pharma exposure without picking individual winners, XLV holds all four stocks above plus the rest of the MFN deal signatories. At around $56, it’s up 1% year-to-date and just saw $361 million in weekly inflows, the largest in months. The ETF’s top holdings are weighted toward the exact companies that signed tariff exemptions, making it a natural vehicle for playing the onshoring theme. Expense ratio is just 0.09%.
Two Names Still on the Outside
Not every pharma giant cut a deal. AbbVie (NYSE:ABBV) and Regeneron Pharmaceuticals (NASDAQ:REGN) are the two major holdouts still in negotiations. Both claim to be in active talks, but neither has signed. At around $210, ABBV trades 14% below its October 2025 all-time high. Its Humira franchise — once the world’s best-selling drug — has already faced biosimilar erosion, and a 100% tariff on imported ingredients would compound the pressure.
If AbbVie signs before July 31, the stock could rally hard as the overhang lifts. If it doesn’t, the math gets ugly fast.
Stephen Ubl, CEO of pharmaceutical trade group PhRMA, warned that tariffs "on cutting-edge medicines will increase costs and could jeopardize billions in U.S. investments." He’s not wrong about the risk for non-deal companies. But for the 13 firms already inside the tariff wall, the competitive advantage is enormous.
The Bear Case: Innovation Risk
My biggest concern isn’t the tariffs themselves — it’s the MFN pricing framework they enforce. Aligning U.S. drug prices with the lowest prices in other developed countries could squeeze margins on future drug launches. One 2020 American Action Forum projection estimated that MFN pricing applied just to Medicare Part B drugs could result in 60 fewer drug launches over a decade. Applied more broadly, the chilling effect on innovation could be material.
There’s also the retaliation risk. The EU and Japan could counter with tariffs targeting American agricultural exports or tech services, complicating the global trade environment further.
And the 120-day implementation window creates a near-term distortion. Distributors and pharmacies are likely already stockpiling imported drugs before the July 31 deadline, which could inflate import data temporarily and create logistics bottlenecks at major ports.
What to Watch
Three catalysts will determine how this trade plays out. First, watch for AbbVie and Regeneron to announce MFN deals before the July 31 deadline — if they do, the entire pharma sector gets a sentiment boost. Second, Eli Lilly’s April 30 earnings will be the first major test of whether the post-tariff, post-obesity-pill-approval narrative can translate into numbers. Third, track the Commerce Department’s onshoring guidelines, expected in the coming weeks, which will define exactly what qualifies as "domestic manufacturing" — a strict definition benefits incumbent U.S. producers; a loose one dilutes the advantage.
The tariff wall is up. Whether you’re buying LLY for the growth, JNJ for the stability, or XLV for the broad exposure, the question isn’t whether pharma is investable — it’s which side of the wall you’re on.
